What’s new in dementia this week
Ireland: Dementia in the media this week
1. ‘HSE to establish register to help people with dementia
2. ‘The screaming will go on for hours until she falls asleep' - Ex-Mrs Brown's Boys star Rory Cowan on coping with his mother's dementia’
3. ‘10 things to know about dementia
4. ‘Living well with dementia strategy
5. Alzheimer Society of Ireland advocates Helen Rochford Brennan and Sean Dónal O’ Shea speak on RTE’s The Today Show.
Watch their interview here https://www.rte.ie/player/ie/show/today-with-maura-and-daithi-30001768/10781255/ (Interview begins at 1.09.17)
Ireland: Upcoming Events
1. DDNI Conference November 30th 2017
The Dementia and Neurodegeneration Network Ireland (DNNI), in partnership with the Alzheimer Society of Ireland and SPHeRE, will host their inaugural conference on 'Building Platforms for Sustainable Research in Dementia and Neurodegeneration'.
The conference wil be held on November 30th 2017 in the Dining Hall at Kings Inn’s, Dublin 1.
To register please see https://www.eventbrite.ie/e/dnni-conference-2017-tickets-37728733658
2. Dementia Masterclass November 27th-29th 2017
The Centre for Economic and Social Research on Dementia at NUI Galway are hosting a three day Dementia Masterclass from 27-29th November in NUI Galway. The event is supported by the GBHI and the University of California, San Francisco.
Places are limited to 50 participants.
To register your interest contact .
UK: Dementia in the media this week
1. ‘Dementia becomes leading cause of death for Australian women
Worldwide: General news
1. ‘Why We Should All Beware The Financial Costs Of Dementia
2. New edition of Alzheimer Europe magazine
Alzheimer Europe has published the 25th edition of its ‘Dementia in Europe’ magazine.
3. Axovant’s experimental AD drug fails
‘Axovant Sciences, a clinical-stage biopharmaceutical company developing novel therapeutic solutions to treat dementia, announced results of its MINDSET Phase 3 clinical trial for the treatment of mild to moderate Alzheimer’s disease.
This Phase 3 study was a randomised, double-blind, placebo-controlled trial evaluating the efficacy, safety and tolerability of intepirdine as an adjunctive therapy to donepezil in people with mild to moderate Alzheimer’s disease.
Although the drug was well tolerated, it failed to demonstrate a statistically significant improvement in cognition and measures in daily activities at 24 weeks compared to participants treated with placebo.
Currently, the company is advancing the HEADWAY Phase 2 trial evaluating intepirdine in people with dementia with Lewy Bodies. The results are expected at the end of the year’ (Alzheimer Europe).